A negative-EV, pre-revenue obesity/MASH pipeline with eye-catching early signals—but survival hinges on funding and Phase 2/3 proof against GLP-1 giants.
Overview
MetaVia (MTVA) is a Cambridge-based, clinical-stage biotech that rebranded from NeuroBo Pharmaceuticals in Nov 2024 to focus on cardiometabolic disease—specifically obesity and MASH—rather than prior viral/neurodegenerative efforts. The company is pre-revenue and depends on equity financing, partnerships, and out-licensing to fund development. Its investment case centers on two pipeline assets: (1) DA-1726, a once-weekly injectable dual GLP-1/glucagon agonist designed with a 3:1 potency ratio intended to deliver strong weight loss plus energy-expenditure and hepatic/visceral fat benefits while limiting hyperglycemia; and (2) vanoglipel (DA-1241), an oral GPR119 agonist in Phase 2a for MASH with reported endpoint success and improvements in ALT and steatosis metrics. A key strategic stabilizer is the relationship with Dong-A ST (major shareholder), which supplies manufacturing and research infrastructure through a shared services agreement. Despite promising early clinical signals and a large market opportunity, MetaVia is financially distressed: auditors flag going-concern risk, the company executed a 1-for-11 reverse split to maintain Nasdaq compliance, and recent fundraising has been dilutive, with runway guided only into Q3 2026.